ObjectiveGI, the integrated research and technology services platform company, announced today its 10th “Center of Research Excellence.
NASHVILLE, TN, September 17, 2019 – ObjectiveGI, the integrated research and technology services platform company, announced today its 10th “Center of Research Excellence.” ObjectiveGI is a physician-partnered model that seamlessly integrates gastroenterology (GI) research services into local practices, providing clinical research as a management option for specialists in support of patient care and practice enhancement. With this 10th center, the company is now partnering with more than 100 GI physicians across the country, broadening their offerings, improving care for patients, and increasing support for referring physicians.
“It’s an exciting time to be in healthcare and support science at the point of care,” says Colleen Hoke, president and CEO, ObjectiveGI. “By partnering with leading GI physicians to create cutting-edge programs, we’re working together to provide the necessary data aimed at developing new NASH therapies and, ultimately, improving patient outcomes.”
Since launching the first “Center of Research Excellence” in 2018, ObjectiveGI and its partners have supported value-based care initiatives for more than 3,000 patients. Today, these centers can be found on-site at GI practices located in Alabama, Arkansas, Florida, Maryland, Michigan, North Carolina, South Carolina and Tennessee. Looking forward, ObjectiveGI plans to double the number of “Center of Excellence” sites by the end of 2020, expanding its transformative presence while driving meaningful partnerships and improved patient outcomes.
“We will continue to add value for all stakeholders and advance emerging care solutions for patients through each one of our research partnerships,” says Dr. Don Lazas, chief medical officer, ObjectiveGI. “Aligning incentives for research sponsors and payers, while providing a premier research infrastructure that allows for GI providers to conduct pivotal clinical trials within the workflow of their practices, remains at the forefront of the work with our physician partners.”
NASH is a silent chronic disease that affects tens of thousands of Americans and will soon be the leading indication for liver transplantation in the U.S. The pharmaceutical industry’s estimated investment in NASH research will eclipse $30 billion, meanwhile the disease costs the U.S. healthcare system nearly $300 billion annually in direct and indirect costs due to related comorbid disease outcomes (CNBC, 2018). There are currently no FDA-approved treatments that exist for NASH; however, more than 50 molecules are in various stages of clinical trials.
About ObjectiveGI
ObjectiveGI, Inc. is an integrated research and technology services platform company that establishes “Center of Research Excellence” partnerships with gastroenterology physician practices, providing research infrastructure, optimal trial selection, study implementation and key research personnel management. Its proprietary processes and technology eliminate the healthcare workflow disruptions commonly associated with clinical trials, thus enabling the delivery of a valuable ancillary vertical that transforms care and improves health outcomes. ObjectiveGI’s initial focus is NonAlcoholic SteatoHepatitis (NASH), a silent chronic disease that affects millions of Americans. Learn more about ObjectiveGI at www.ObjectiveGI.com.
Contacts:
Colleen Hoke, ObjectiveGI
colleen.hoke@objectivegi.com
Jillian Hammell, Crowley Webb
Jillian.hammell@crowleywebb.
